AstraZeneca gets European regulatory nod for oral diabetes treatment

Writer, Stock Market Wire
Friday, February 1, 2019 - 13:59

AstraZeneca said European regulators had offered a positive opinion for the oral use of its treatment for type-one diabetes.

The Committee for Medicinal Products for Human Use of the European Medicines Agency had also recommended a new indication for the marketing authorisation of the treatment, Forxiga. Forxiga was the first oral medicine to receive a positive recommendation from the EMA for use in type-one diabetes as an adjunct to insulin, when insulin alone did not provide adequate glycaemic control.

'People with type-one diabetes have not seen oral treatment innovation in decades and we believe today's announcement signals an important advancement for them, as well as a broader understanding of the well-established clinical profile of Forxiga for people living with metabolic diseases,' head of cardiovascular, renal and metabolism Elisabeth Bjork said.

At 1:59pm: (LON:AZN) AstraZeneca PLC share price was +33.5p at 5565.5p


Related content

AstraZeneca, MSD advanced breast cancer treatment gets EU regulatory nod

AstraZeneca and MSD said the European Commission had approved their drug to treat patients with advanced breast cancer.

The approval was based on data...

Wed, 10/04/2019 - 07:14


Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLC

Liberum Capital today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 6400p (from 5800p).

Broker Forecasts data provided...

Fri, 05/04/2019 - 08:50


AstraZeneca shares take a knock on Japanese deal mechanics

AstraZeneca (AZN) £61.67

Loss to date: 2.1%

Original entry point: Buy at £63.00, 15 November 2018


AstraZeneca’s (...

Thu, 04/04/2019 - 00:00


Broker Forecast - HSBC issues a broker note on AstraZeneca PLC

HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5180p (from 5140p).

Broker Forecasts data provided by...

Tue, 02/04/2019 - 11:20


Broker Forecast - UBS issues a broker note on AstraZeneca PLC

UBS today downgrades its investment rating on AstraZeneca PLC (LON:AZN) to sell (from neutral) and cut its price target to 5400p (from 5900p).

Broker Forecasts...

Tue, 02/04/2019 - 09:50